Neuromyelitis optica (NMO) is an uncommon disease syndrome of the central nervous system (CNS) that affects the optic nerves and spinal cord. Individuals with NMO develop optic neuritis, which causes pain in the eye and vision loss, and transverse myelitis, which causes weakness, numbness, and sometimes paralysis of the arms and legs, along with sensory disturbances and loss of bladder and bowel control. NMO leads to loss of myelin, which is a fatty substance that surrounds nerve fibers and helps nerve signals, move from cell to cell. The syndrome can also damage nerve fibers and leave areas of broken-down tissue. In the disease process of NMO, for reasons that arent yet clear, immune system cells and antibodies attack and destroy myelin cells in the optic nerves and the spinal cord.
Neuromyelitis optica drug is drug used in the treatment of neuromyelitis optica, in this report we focused on Glucocorticoids such as Methylprednisolone and Immunoglobulin such as IVIg.
The report offers detailed coverage of Neuromyelitis Optica Drug industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Neuromyelitis Optica Drug by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
The report forecast global Neuromyelitis Optica Drug market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2020-2028.
First, this report covers the present status and the future prospects of the global Neuromyelitis Optica Drug market for 2015-2028.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].
Key Companies
Pfizer
FRESENIUS
TEVA
SANDOZ
Intas
Gyjtrs
NANG KUANG
Tianjin Kingyork
Baxter
CSL
Grifols
Octapharma
CBOP
At the same time, we classify Neuromyelitis Optica Drug according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.
Market by Order Type
Glucocorticoids
Immunoglobulin
Market by Application
Acute attack
Remission prophylactic treatment
Market Segment as follows:
By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]
The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the Neuromyelitis Optica Drug market for the forecast period 2020 - 2028?
• What are the driving forces in the Neuromyelitis Optica Drug market for the forecast period 2020 - 2028?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the Neuromyelitis Optica Drug industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?